share_log

CRISPR Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Patel Naimish

SEC announcement ·  May 29 10:31
Summary by Futu AI
CRISPR Therapeutics AG, represented by Naimish Patel, the company's Chief Medical Officer, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 28, 2024. The Form 3 filing indicates that Patel does not beneficially own any non-derivative or derivative securities of CRISPR Therapeutics. This standard disclosure is required under Section 16(a) of the Securities Exchange Act of 1934 and is a routine filing for officers of publicly traded companies to report securities holdings and transactions to the SEC.
CRISPR Therapeutics AG, represented by Naimish Patel, the company's Chief Medical Officer, has filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 28, 2024. The Form 3 filing indicates that Patel does not beneficially own any non-derivative or derivative securities of CRISPR Therapeutics. This standard disclosure is required under Section 16(a) of the Securities Exchange Act of 1934 and is a routine filing for officers of publicly traded companies to report securities holdings and transactions to the SEC.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.